Gonadotrophin releasing hormone agonist treatment with or without recombinant human GH in adopted children with early puberty

Clin Endocrinol (Oxf). 2001 Jul;55(1):121-9. doi: 10.1046/j.1365-2265.2001.01315.x.

Abstract

Background: Early onset of puberty is frequently observed in adopted children. During treatment with a gonadotrophin releasing hormone agonist (GnRHa), a decrease in height velocity (HV) precludes height gain.

Objective and design: We studied the effect of the addition of GH to GnRHa treatment in a 3-year prospective randomized trial in 30 adopted children with early puberty.

Patients: Mean age (SD) at start of treatment was 9.6 (0.9) years in girls and predicted adult height (PAH) using a segmented bone age (BA) assessment method was 148.0 (5.3) cm.

Results: HV decreased gradually in both groups with a higher HV in the group with GH addition (group B). No significant difference between the rates of bone maturation [change in bone age (DeltaBA)/change in chronological age (DeltaCA)] of both treatment groups was observed. After 3 years of treatment, PAH increase was 5.7 (3.8) cm in group A (GnRHa alone) and 10.1 (3.8) cm in group B (P < 0.01). IGF-I levels were higher in group B. HV decreased slowly in both groups during treatment, unlike stabilization of IGF-I levels.

Conclusion: We conclude that, after 3 years of treatment, the addition of GH to GnRHa results in higher HV and a significant increase in PAH compared to GnRHa alone.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adoption*
  • Anthropometry
  • Body Height / drug effects
  • Child
  • Drug Therapy, Combination
  • Emigration and Immigration
  • Female
  • Follow-Up Studies
  • Growth / drug effects
  • Human Growth Hormone / therapeutic use*
  • Humans
  • Luteolytic Agents / therapeutic use*
  • Male
  • Prospective Studies
  • Puberty, Precocious / drug therapy*
  • Puberty, Precocious / physiopathology
  • Triptorelin Pamoate / therapeutic use*

Substances

  • Luteolytic Agents
  • Triptorelin Pamoate
  • Human Growth Hormone